Asthma drug shows promise for rare genetic disorder
NCT ID NCT03029429
First seen Jan 11, 2026 · Last updated May 12, 2026 · Updated 17 times
Summary
This study tests whether theophylline, a drug used for asthma, can help people with pseudohypoparathyroidism lose weight and improve blood sugar control. The trial involves 29 obese teenagers and young adults aged 13 and older. Researchers will measure changes in body mass index and glucose tolerance over the treatment period.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSEUDOHYPOPARATHYROIDISM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Jaclyn Tamaroff
Nashville, Tennessee, 37212, United States
Conditions
Explore the condition pages connected to this study.